Company / Operating Cash Flow
Seres Therapeutics, Inc. Operating Cash Flow History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$117.4M
FY2025
5-year range
-$117.4M / $6.7M
FY2021-FY2025
Trend
-1854.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow changed -1855% YoY in FY2025, a notable deviation from the 9-year average annual change of -248%.
Based on SEC 10-K filings.
-$117M in FY2025.
Declined from -$94M to -$117M over the past 3 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 1854.7% year-over-year.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$117.4M | -1854.7% |
| FY2023 | $6.7M | +107.1% |
| FY2022 | -$93.6M | -22.3% |
| FY2021 | -$76.5M | -21.7% |
| FY2020 | -$62.9M | +16.8% |
| FY2019 | -$75.5M | -272.0% |
| FY2018 | $43.9M | +207.5% |
| FY2017 | -$40.8M | -294.3% |
| FY2016 | -$10.4M | -94.7% |
| FY2015 | -$5.3M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026